Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.6207
USD
|
-1.87%
|
|
-7.36%
|
-16.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
38.59
|
86.15
|
53.27
|
13.51
|
15.66
|
13.09
|
-
|
-
|
Enterprise Value (EV)
1 |
38.59
|
86.15
|
53.27
|
13.51
|
15.66
|
13.09
|
13.09
|
13.09
|
P/E ratio
|
-0.26
x
|
-3.33
x
|
-2.66
x
|
-0.71
x
|
-0.83
x
|
-0.72
x
|
-0.75
x
|
-0.77
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17.7
x
|
373
x
|
236
x
|
59.8
x
|
69.3
x
|
62.3
x
|
43.6
x
|
43.6
x
|
EV / Revenue
|
17.7
x
|
373
x
|
236
x
|
59.8
x
|
69.3
x
|
62.3
x
|
43.6
x
|
43.6
x
|
EV / EBITDA
|
-1.78
x
|
-3.45
x
|
-3.23
x
|
-0.69
x
|
-0.77
x
|
-0.56
x
|
-0.46
x
|
-0.39
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,718
|
12,330
|
20,891
|
20,926
|
21,003
|
21,086
|
-
|
-
|
Reference price
2 |
5.745
|
6.987
|
2.550
|
0.6457
|
0.7456
|
0.6207
|
0.6207
|
0.6207
|
Announcement Date
|
3/24/20
|
3/11/21
|
3/17/22
|
3/16/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.183
|
0.231
|
0.226
|
0.226
|
0.226
|
0.21
|
0.3
|
0.3
|
EBITDA
1 |
-21.68
|
-24.98
|
-16.48
|
-19.61
|
-20.28
|
-23.5
|
-28.6
|
-33.2
|
EBIT
1 |
-21.7
|
-24.99
|
-16.5
|
-19.63
|
-20.3
|
-23.5
|
-28.6
|
-33.2
|
Operating Margin
|
-994%
|
-10,819.48%
|
-7,299.12%
|
-8,684.51%
|
-8,981.42%
|
-11,190.48%
|
-9,533.33%
|
-11,066.67%
|
Earnings before Tax (EBT)
1 |
-21.49
|
-25.15
|
-16.16
|
-18.96
|
-18.95
|
-23.3
|
-28.4
|
-33
|
Net income
1 |
-21.5
|
-25.16
|
-16.16
|
-18.96
|
-18.95
|
-23.3
|
-28.4
|
-33
|
Net margin
|
-985.02%
|
-10,890.48%
|
-7,151.77%
|
-8,391.15%
|
-8,384.07%
|
-11,095.24%
|
-9,466.67%
|
-11,000%
|
EPS
2 |
-22.35
|
-2.100
|
-0.9600
|
-0.9100
|
-0.9000
|
-0.8650
|
-0.8300
|
-0.8100
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/20
|
3/11/21
|
3/17/22
|
3/16/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.057
|
0.056
|
0.056
|
0.057
|
0.057
|
0.056
|
0.056
|
0.057
|
0.057
|
0.056
|
0.06
|
0.06
|
0.06
|
0.06
|
EBITDA
|
-3.987
|
-3.759
|
-4.129
|
-4.116
|
-5.638
|
-5.73
|
-6.134
|
-
|
-5.084
|
-4.458
|
-
|
-
|
-
|
-
|
EBIT
|
-3.99
|
-3.763
|
-4.132
|
-4.12
|
-5.641
|
-5.734
|
-6.137
|
-4.61
|
-5.089
|
-4.462
|
-
|
-
|
-
|
-
|
Operating Margin
|
-7,000%
|
-6,719.64%
|
-7,378.57%
|
-7,228.07%
|
-9,896.49%
|
-10,239.29%
|
-10,958.93%
|
-8,087.72%
|
-8,928.07%
|
-7,967.86%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-3.453
|
-3.764
|
-4.122
|
-4.024
|
-5.398
|
-5.42
|
-5.775
|
-4.25
|
-4.739
|
-4.184
|
-
|
-
|
-
|
-
|
Net income
|
-3.453
|
-3.764
|
-4.122
|
-4.024
|
-5.398
|
-5.42
|
-5.775
|
-4.25
|
-4.739
|
-4.184
|
-
|
-
|
-
|
-
|
Net margin
|
-6,057.89%
|
-6,721.43%
|
-7,360.71%
|
-7,059.65%
|
-9,470.18%
|
-9,678.57%
|
-10,312.5%
|
-7,456.14%
|
-8,314.04%
|
-7,471.43%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2200
|
-0.1600
|
-0.2000
|
-0.1900
|
-0.2600
|
-0.2600
|
-0.2800
|
-0.2000
|
-0.2300
|
-0.2000
|
-0.2300
|
-0.2500
|
-0.2800
|
-0.2900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
3/17/22
|
5/11/22
|
8/11/22
|
11/14/22
|
3/16/23
|
5/15/23
|
8/10/23
|
11/14/23
|
4/1/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/20
|
3/11/21
|
3/17/22
|
3/16/23
|
4/1/24
|
-
|
-
|
-
|
Last Close Price
0.6207
USD Average target price
8
USD Spread / Average Target +1,188.87% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.75% | 13.09M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|